Drug-drug Interaction Study With AZD5335 and Itraconazole in Participants With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
NCT07402915 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24
Last updated 2026-05-20
Summary
The purpose of this study is to assess the effect of itraconazole on the pharmacokinetics (PK) of AZ14170132.
Conditions
- Fallopian Tube Cancer
- Ovarian Cancer
- Primary Peritoneal
Interventions
- DRUG
-
AZD5335
AZD5335 will be administered as IV infusion.
- DRUG
-
Itraconazole
Itraconazole capsule will be administered orally.
Sponsors & Collaborators
- lead INDUSTRY
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SEQUENTIAL
Eligibility
- Min Age
- 18 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2026-01-26
- Primary Completion
- 2027-10-15
- Completion
- 2027-10-15
Countries
- Georgia
- Ireland
- Portugal
- Spain
Study Locations
More Related Trials
-
First-in-human Phase I Study to Evaluate Safety, Tolerability and Antineoplastic Activity of OATD-02 in Patients with Selected Advanced And/or Metastatic Solid Tumours
NCT05759923 ·Status: RECRUITING ·Phase: PHASE1
-
ZD9331 With or Without Topotecan in Treating Patients With Refractory or Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
NCT00014690 ·Status: COMPLETED ·Phase: PHASE2
-
Topotecan and Gefitinib (Iressa) for Ovarian, Peritoneal, or Fallopian Tube Cancer
NCT00317772 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
NCT01381861 ·Status: COMPLETED ·Phase: PHASE2
-
AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer
NCT07218809 ·Status: RECRUITING ·Phase: PHASE3
-
Tamoxifen and SUBA-Itraconzole Combination Testing in Ovarian Cancer
NCT05156892 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Saracatinib and Paclitaxel in Platinum-resistant Ovarian Cancer
NCT01196741 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
AZD2171 in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer
NCT00275028 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase II Study of ZD1839 and Tamoxifen in Patients With Epithelial Ovarian Carcinoma, Cancer of the Fallopian Tube or the Peritoneum Refractory to Platinum- and Taxane-based Therapy
NCT00189358 ·Status: COMPLETED ·Phase: PHASE2
-
Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Ovarian Cancer
NCT00003532 ·Status: TERMINATED ·Phase: PHASE2
-
Study of Azacitidine and Durvalumab in Advanced Solid Tumors
NCT02811497 ·Status: COMPLETED ·Phase: PHASE2
-
S0025 Irinotecan in Treating Patients With Refractory Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
NCT00053833 ·Status: TERMINATED ·Phase: PHASE2
-
Platinum-based Chemotherapy With Atezolizumab and Niraparib in Patients With Recurrent Ovarian Cancer
NCT03598270 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast Cancer
NCT03292172 ·Status: TERMINATED ·Phase: PHASE1
-
A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
NCT05128825 ·Status: RECRUITING ·Phase: PHASE2
-
Feasibility Trial of Intraperitoneal Chemotherapy for Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma
NCT00582205 ·Status: TERMINATED ·Phase: PHASE2
-
Real-life Data of Olaparib in Relapsed Ovarian Cancers Patients
NCT04152941 ·Status: COMPLETED
-
Repurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian Cancer
NCT05998135 ·Status: RECRUITING ·Phase: PHASE2
-
Cisplatin and Gemcitabine in Treating Patients With Refractory or Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
NCT00003358 ·Status: COMPLETED ·Phase: PHASE1
-
Topotecan in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
NCT00005029 ·Status: TERMINATED ·Phase: PHASE2
-
Erlotinib or Observation in Treating Patients Who Have Undergone First-Line Chemotherapy for Ovarian Cancer, Peritoneal Cancer, or Fallopian Tube Cancer
NCT00263822 ·Status: COMPLETED ·Phase: PHASE3
-
Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation
NCT02953457 ·Status: COMPLETED ·Phase: PHASE2
-
Taurolidine in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
NCT00021034 ·Status: COMPLETED ·Phase: PHASE1
-
Atezolizumab With Bevacizumab and Chemotherapy vs Bevacizumab and Chemotherapy in Early Relapse Ovarian Cancer
NCT03353831 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer
NCT04486352 ·Status: RECRUITING ·Phase: PHASE1/PHASE2